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Abstract
Introduction: The aims of this study were to assess agreement between the currently used 2002 American–
European Consensus Group (AECG) classification criteria and the new 2012 American College of Rheumatology
(ACR) criteria for Sjögren’s syndrome (SS) and to identify potential sources of disagreement.
Methods: We studied 105 patients between 2006 and 2013 from the Brittany cohort of patients with suspected SS.
AECG criteria were applied using only Schimer’s test and unstimulated whole salivary flow (UWSF) to assess
objective ocular and oral involvement, since these are the tests most physicians use in clinical practice. Agreement
between the two sets of criteria was assessed using Cohen’s κ coefficient.
Results: Of those studied, 42 patients fulfilled AECG and 35 ACR criteria. Agreement between the two sets was
moderate (κ = 0.53). Patients fulfilling ACR but not AECG criteria (n = 8) were significantly younger and had shorter
symptom durations, but only three of them had SS in the opinion of the evaluating physician. Xerostomia and
xerophthalmia (AECG set only) did not discriminate between patients with and without SS. The use of UWSF in the
AECG but not the ACR criteria explained part of the disagreement. The serological item in the ACR set (positive
rheumatoid factor and antinuclear antibody ≥1:320 or anti-SSA/SSB positivity) did not result in classification
differences compared to anti-SSA/SSB antibody alone (AECG set). Agreement between ocular staining score ≥3
(ACR set) and Schirmer’s test ≤5 mm/5 min (AECG set) was very low (κ = 0.14).
Conclusions: Agreement was only moderate between ACR and AECG criteria, suggesting these two sets would not
select comparable patient populations. An international consensus about which classification criteria should be
used in clinical studies is needed.
Introduction
The classification criteria for Sjögren’s syndrome (SS) issued
in 2002 by the American–European Consensus Group
(AECG) have been widely used in clinical studies over the
last decade [1]. In 2012, the Sjögren’s International Colla-
borative Clinical Alliance issued new classification criteria,
which have been endorsed by the American College of
Rheumatology (ACR) [2]. These new criteria are intended
for use in patients referred to specialists because of signs or
symptoms suggesting SS. They were developed by asking
experts in rheumatology, ophthalmology and oral medicine
to select the items they felt were most relevant.
The new criteria differ substantially from the 2002
AECG criteria in three ways: they include no subjective
ocular and oral symptoms and no functional or morpho-
logical tests for the salivary glands; they use a new ocular
staining score (OSS) [3] as the only criterion for ocular
involvement; and they allow the use of an antinuclear
antibody (ANA) titer ≥1:320 plus rheumatoid factor (RF)
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positivity as an alternative to anti-SSA/SSB antibody
positivity for the assessment of systemic autoimmunity.
Here, our objectives were to evaluate agreement be-
tween the two criteria sets and to identify sources of
disagreement.
Methods
Study population
We studied the single-centre Brittany cohort of patients
with suspected SS included between November 2006
and March 2013 in Brittany, France. The inclusion cri-
teria are described elsewhere [4]. Briefly, patients were
addressed to our consultation by their family physician,
rheumatologist, internist, dentist or ophthalmologist if
SS was suspected due to sicca complaints, major salivary
gland swelling, suggestive extraglandular features or sug-
gestive autoantibodies. Written consent was obtained
from all participants, and the study was approved by the
local ethics committee (Brest University Hospital).
This study included 105 patients of the cohort who
had all the tests available to apply both ACR and AECG
criteria, including 99 (94.3%) women. Mean age was
57.2 ± 13.7 years and mean symptom duration was 6.7 ±
6.1 years.
Clinical evaluation and laboratory tests
Schirmer’s test was considered abnormal if ≤5 mm/5 mi-
nute and the unstimulated whole salivary flow if <0.1 ml/
minute. ANAs were assessed on HEp-2 cells and anti-SSA
and anti-SSB antibodies using commercial enzyme-linked
immunosorbent assays, and RF (IgM and IgA isotypes)
using in-house enzyme-linked immunosorbent assays.
Minor labial salivary gland biopsy was performed in all pa-
tients and graded according to the semi-quantitative score
of Chisholm and Mason [5]. Salivary gland biopsy grades
3 and 4 indicating focus scores ≥1/4 mm2 were considered
abnormal.
Ophthalmologic evaluation
All patients underwent a slit-lamp examination by an oph-
thalmologist experienced in dry-eye diseases. The corneal
fluorescein pattern was graded from 0 (no punctate epi-
thelial erosions) to 3 (severe keratitis). A drop of lissamine
green dye was then instilled into the inferior conjunctival
fornix of each eye, the patient was asked to blink several
times, and the nasal and temporal bulbar conjunctivae
were then immediately graded semi-quantitatively from
0 (no staining) to 3 (diffuse dot staining or confluent
staining).
The Sjögren’s International Collaborative Clinical Alli-
ance OSS [3] was published during the inclusion period
for our cohort. We retrospectively computed the OSS of
both eyes as the 0 to 12 sum of the 0 to 3 lissamine green
scores for the nasal and temporal conjunctiva (range, 0 to
6) plus the 0 to 3 fluorescein score for each cornea multi-
plied by 2 (because the specific patterns of corneal fluores-
cein staining giving additional points in the OSS (central
staining, filaments or confluent staining) were not de-
scribed in our protocol). OSS ≥3 in at least one eye was
considered abnormal.
Case ascertainment
Table 1 presents the rules for classification using the
AECG and ACR criteria sets. AECG criteria were applied
using only Schirmer’s test and unstimulated whole salivary
flow, which are the tests we use in clinical practice to as-
sess objective ocular and salivary gland involvement.
The evaluating physician was also asked to define the
most probable diagnosis in his opinion for each patient,
without referring to specific classification criteria. All cases
were reviewed by a panel of three experts (VD-P, AS and
SJ-J) to reach consensus. The most probable diagnoses in
the opinion of the experts were SS in 47 (44.8%) patients,
idiopathic sicca syndrome in 37 (35.2%) patients, other
connective tissue diseases in 11 (10.5%) patients and drug-
induced sicca syndrome in 10 (9.5%) patients.
This clinical definition of SS cases was not used as a
gold standard to compare the diagnostic performance of
AECG criteria and ACR criteria in terms of sensitivity
and specificity, since the physician most probably used,
even subconsciously, current validated classification cri-
teria (that is, AECG criteria) to perform his diagnosis,
leading to circular reasoning that would have overesti-
mated AECG performance to the detriment of ACR
criteria.
Statistical analysis
Statistical tests were performed using the Statistical Pack-
age for the Social Sciences (SPSS 18.0, 2009; SPSS Inc.,
Chicago, IL, USA). Quantitative variables were described
as mean ± standard deviation and qualitative variables as
number (%). Agreement between classification criteria sets
and between criteria was evaluated using Cohen’s kappa
coefficient (κ). To compare patient groups, we used the
Mann–Whitney test, Fisher’s exact test or the chi-square
test as appropriate.
Results
Classification criteria
Of the 105 patients, 42 (40.0%) fulfilled the AECG cri-
teria and 35 (33.3%) fulfilled the ACR criteria (Table 2).
Agreement between the two criteria sets was moderate
(κ = 0.53). Patients fulfilling only the ACR criteria were
significantly younger and had shorter symptom dura-
tions than did patients fulfilling the AECG criteria
(mean age, 46.6 ± 15.8 vs. 60.0 ± 11.4 years; and mean
symptom duration, 2.9 ± 2.4 vs. 7.7 ± 6.8 years; P < 0.001
for both comparisons).
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Description of the patients with discordant classification
Table 3 details the features of the eight patients fulfilling
ACR criteria but not AECG criteria and of the 15 patients
fulfilling AECG criteria but not ACR criteria. All patients
fulfilling only AECG criteria had sicca complaints, either
abnormal unstimulated whole salivary flow or Schirmer’s
test, and either anti-SSA/SSB antibodies or abnormal sal-
ivary gland biopsy. Five of them had extraglandular in-
volvement, and all of them had SS in the opinion of the
evaluating physician.
Among the eight patients fulfilling only ACR criteria,
none of them had abnormal unstimulated whole salivary
flow or Schirmer’s test, but seven had abnormal salivary
gland biopsy. Only three of them had SS according to
the physician’s opinion, and other more likely diagnoses
were rheumatoid arthritis (n = 2), systemic lupus erythe-
matosus (n = 1), undifferentiated connective tissue dis-
ease (n = 1) and idiopathic sicca syndrome (n = 1).
Subjective sicca complaints (AECG set only)
The subjective sicca symptoms (xerophthalmia and xer-
ostomia) were noted in nearly all of the patients (re-
spectively in 92.4% and 94.3%), suggesting no ability of
these symptoms to discriminate between patients with
Table 1 Pragmatic AECG [1] and ACR [2] classification criteria for Sjögren’s syndrome
Pragmatic 2002 AECG criteria 2012 ACR criteria
Items 1. Ocular dryness symptoms 1. Positive anti-SSA or anti-SSB antibodies or
positive rheumatoid factor plus ANA ≥1:320
2. Oral dryness symptoms 2. Focus score ≥1 focus/4 mm2 on minor
salivary gland biopsy
3. Ocular signs: Schirmer’s test ≤5 mm/5 minutes 3. Keratoconjunctivitis sicca with ocular
staining score ≥3
4. Focus score ≥1 focus/4 mm2 on minor salivary gland biopsy
5. Salivary gland involvement: unstimulated whole salivary flow ≤0.1 ml/minute
6. Positive anti-SSA or anti-SSB antibodies
Rules for
classification
Presence of any four of the six items with at least item 4 or 6, or presence of any three
of the four objective items (items 3, 4, 5 and 6)
In a patient with suspected Sjögren’s
syndrome, any two of the three items
Exclusion criteria for both criteria sets are head-and-neck radiation, graft-versus-host disease, hepatitis C infection, acquired immunodeficiency syndrome or
sarcoidosis. Pre-existing lymphoma and use of anticholinergic drugs are exclusion criteria only in the AECG criteria, whereas amyloidosis and IgG4-related disease
are exclusion criteria only in the ACR criteria.
We did not use in this study the whole set of AECG criteria, but only the tests we use in clinical practice (pragmatic AECG criteria); that is, only the unstimulated
whole salivary flow to assess salivary gland involvement (and not salivary scintigraphy or parotid sialography which are considered obsolete by most physicians),
and only the Schirmer’s test to assess ocular signs (and not vital dye staining graded according to van Bijsterveld method). ACR, American College of
Rheumatology; AECG, American–European Consensus Group.
Table 2 Characteristics of patients meeting ACR and/or AECG criteria for Sjögren’s syndrome
Patients fulfilling
Both sets ACR set only AECG set only Neither set
(n = 27) (n = 8) (n = 15) (n = 55)
Age (years) 60.7 ± 11.7 46.6 ± 15.8 59.3 ± 11.1 56.4 ± 14.5
Symptom duration (years) 9.5 ± 7.4 2.9 ± 2.4 4.7 ± 4.3 6.4 ± 5.7
Female 25 (92.6) 8 (100) 14 (93.3) 52 (94.5)
Xerophthalmia 26 (96.3) 6 (75.0) 14 (93.3) 50 (90.9)
Xerostomia 27 (100) 6 (75.0) 15 (100) 51 (92.7)
Salivary flow ≤0.1 ml/minute 18 (66.7) 0 (0) 10 (66.7) 16 (29.1)
Schirmer’s test ≤5 mm/5 minutes 22 (81.5) 1 (12.5) 12 (80.0) 13 (23.6)
OSS ≥3 24 (88.9) 6 (75.0) 0 (0) 19 (34.5)
Anti-SSA or anti-SSB positivity 18 (66.7) 4 (50.0) 4 (26.7) 1 (1.8)
ANA ≥1:320 25 (92.6) 5 (62.5) 8 (53.3) 18 (32.7)
RF positivity 14 (51.9) 4 (50.0) 1 (6.7) 6 (10.9)
Anti-SSA/SSB or RF plus ANA ≥1:320 21 (77.8) 4 (50.0) 4 (26.7) 1 (1.8)
Focus score ≥1 24 (88.9) 7 (87.5) 11 (73.3) 6 (10.9)
Data presented as mean ± standard deviation or number (%). Xerophthalmia and xerostomia referred to subjective complaints from the patients. ACR, American
College of Rheumatology; AECG, American–European Consensus Group; OSS, ocular staining score; ANA, antinuclear antibody; RF, rheumatoid factor.
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Table 3 Description of the patients fulfilling only ACR criteria or only AECG criteria
Patient Sex Age
(years)
Duration
(years)a
Eyeb Mouthc Arthritisd Lunge Neurof Parotidg UWSFh Schirmeri OSSj Chisholmk ANA Anti-
SSAl
Anti-
SSBl
RF (n <
0.2)
ACPA (n
< 20)
IgG
(mg/l)
Clinicalm
Detailed characteristics of the eight patients fulfilling only ACR criteria
1 F 25 0 1 0 0 0 0 0 0.35 8 3 1 160 146 46 0.14 9 9.2 SS
2 F 63 1 1 1 0 0 0 0 0.4 30 3 4 1,280 0 0 0 0 5.8 SS
3 F 34 1 1 0 1 0 0 0 0.2 20 4 4 1,280 174 0 0.5 250 16.2 RA
4 F 59 5 0 1 0 0 0 1 0.4 10 1 3 640 140 80 0.9 7 13.4 SS
5 F 61 5 1 1 0 0 0 0 0.5 8 3 3 0 0 0 0 0 12.1 Sicca
6 F 47 4 1 1 0 0 0 0 0.2 30 3 3 1,280 0 0 0 0 16.5 UCTD
7 F 57 1 1 1 1 0 1 0 0.5 30 4 4 160 0 0 0.52 250 12.7 RA
8 F 27 6 0 1 0 1 0 0 0.25 30 0 3 1,280 100 0 0.81 15 18.9 SLE
Detailed characteristics of the 15 patients fulfilling only AECG criteria
1 F 67 1 1 1 0 0 0 0 0.005 5 2 3 160 0 0 0 0 11.7 SS
2 F 45 1 1 1 0 0 0 0 0.001 5 2 2 640 154 0 0.05 0 13 SS
3 F 75 0 1 1 0 0 0 0 0.2 0 2 3 0 0 0 0.34 0 9.3 SS
4 F 56 1 1 1 0 0 0 0 0.005 25 2 2 1,280 24 152 0 0 9.9 SS
5 F 50 13 1 1 0 0 1 1 0.1 20 0 4 160 0 0 0 0 9.1 SS
6 F 69 6 1 1 0 0 0 0 0.25 5 1 4 1,280 0 0 0 0 10.3 SS
7 F 66 1 1 1 1 0 0 0 0.486 5 2 3 320 0 0 0 0 7 SS
8 F 55 7 1 1 0 1 0 0 0.02 15 2 4 160 0 0 0 0 7.1 SS
9 F 43 3 1 1 0 0 0 0 0.15 5 1 1 640 85 0 0 0 12.6 SS
10 F 78 10 1 1 0 0 0 0 0.05 7 2 3 160 0 0 0 0 9.7 SS
11 M 64 2 1 1 0 1 0 0 0.2 0 0 4 320 0 0 0 28 22.6 SS
12 F 60 8 1 1 0 0 1 1 0.05 5 2 3 640 9 32 0 72 8.43 SS
13 F 58 2 1 1 0 0 0 0 0.04 4 0 3 0 0 0 0 0 8.33 SS
14 F 43 10 0 1 0 0 0 0 0.06 0 1 2 320 40 0 0 0 10 SS
15 F 50 1 1 1 0 0 0 0 0.05 15 1 3 0 0 0 0 0 9.7 SS
ACPA, anti-citrullinated peptide antibodies; ACR, American College of Rheumatology; AECG, American–European Consensus Group; ANA, antinuclear antibody; F, female; IgG, serum level of immunoglobulin G; M, male;
OSS, ocular staining score; SS, Sjögren’s syndrome. RA, rheumatoid arthritis; RF, rheumatoid factor; sicca, idiopathic sicca syndrome; SLE, systemic lupus erythematosus; UCTD, undifferentiated connective tissue disease;
UWSF, unstimulated whole salivary flow. aDuration of the symptoms. bXerophthalmia (0, absent; 1, present). cXerostomia (0, absent; 1, present). dPresence of swollen and tender joints on the day of examination.
eIncludes the presence of chronic dry cough or computed tomography-proven interstitial lung disease. fPatient with objective peripheral neuropathy. gPresence or history of parotidomegaly. hAbnormal if ≤0.1 ml/minute.
iSchirmer’s test abnormal if ≤ 5 mm/5 minutes. jAbnormal if ≥ 3. kChisholm’s grading of the lymphocytic infiltration on minor salivary gland biopsy (grades 3 and 4 correspond to a focus score ≥1 focus of more than 50
lymphocytes/4 mm2). lAnti-SSA and anti-SSB antibodies (n < 40). mDiagnosis made by the physician, without reference to specific classification criteria.
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and without SS in this population. The proportions of
patients with xerophthalmia or xerostomia were not sig-
nificantly different in the group fulfilling both criteria
sets and in the group fulfilling neither criteria set (P =
0.35 and P = 0.2, respectively).
Functional salivary-gland assessment (AECG set only)
Salivary flow was decreased in 66.7% of patients fulfilling
both criteria sets and in 29.4% of those fulfilling neither
criteria set (P = 0.001). No patient fulfilling only the
ACR set had a decrease in salivary flow.
Serological criterion
Only three patients had positive RF plus ANA ≥ 1:320
but negative anti-SSA antibodies; that is, met the ACR
serological criterion but not the AECG serological criter-
ion. These three patients fulfilled the AECG criteria;
they also fulfilled the ACR criteria even without taking
RF and ANA into account, since they all had abnormal
OSS and focus score results.
Ophthalmological criterion
Agreement between the OSS (ACR set) and Schirmer’s test
(AECG set) was very low (κ = 0.14). Agreement with the
salivary gland biopsy was lower for the OSS than for Schir-
mer’s test (κ = 0.14 vs. 0.35, respectively). Both the OSS and
Schirmer’s test showed poor agreement with anti-SSA/SSB
positivity (κ = 0.21 and κ = 0.27 respectively).
Discussion
In this study, agreement was only moderate between the
AECG and ACR criteria sets. The AECG criteria set
classified more patients as having SS, whereas the ACR
criteria set seemed to classify patients earlier in the
course of the disease but included patients who did not
have SS in the opinion of the physician. These discrep-
ancies were chiefly ascribable to the absence in the ACR
set of functional salivary gland testing (such as salivary
flow measurement) and, above all, to the intrinsic differ-
ences between the OSS and Schirmer’s test.
These two ocular dryness tests had very low agreement.
According to the latent class analysis method used to de-
velop the ACR classification criteria [2], the OSS had
89.7% sensitivity but only 37.8% specificity for SS, whereas
Schirmer’s test had a lower sensitivity of 42.7% but a better
specificity of 75.1%. In our study, in patients fulfilling nei-
ther criteria set (and who were therefore unlikely to be di-
agnosed with SS), an abnormal OSS was more common
than an abnormal Schirmer’s test, suggesting lower specifi-
city of the OSS. To compare the diagnostic usefulness of
these two tests, we did not use the physician’s diagnosis as
the reference, since this diagnosis relied chiefly on
Schirmer’s test and not on the OSS. Instead, we evaluated
the agreement of the ocular dryness tests with the focus
score and anti-SSA/SSB positivity, two major diagnostic
features of SS [6] that served as external validation criteria.
Compared with the OSS, Schirmer’s test showed slightly
better agreement with the focus score.
In the recently published study by Rasmussen and
colleagues, the discordance between AECG and ACR
criteria was also mostly attributed to the differences be-
tween the tests assessing the objective ocular component
[7]. In their study, OSS displayed a poor specificity for
SS (45 to 51%), which could be partially corrected by in-
creasing its positivity cutoff value from ≥ 3 to ≥ 4/12.
A complete ophthalmological evaluation is mandatory
in patients with suspected SS, in particular to assess eye-
lid diseases and the differential diagnoses of keratocon-
junctivitis sicca. However, classification tools should rely
on the most specific items. Advantages of Schirmer’s test
include ease of use, even at the bedside in any clinical
ward where trained staff members are available, and
good performance as a screening tool for SS [8].
The serological item of the AECG criteria could prob-
ably be improved, since roughly 40% of primary SS pa-
tients do not have anti-SSA/SSB antibodies. However,
we have shown here that the adjunction of ANA and RF,
as proposed in the ACR criteria, did not modify the clas-
sification potential of anti-SSA/SSB alone. Other tests
should be evaluated when new classification criteria will
be developed, such as blood B-cell phenotyping [9] or
other autoantibodies [10].
Another intrinsic difference between the AECG cri-
teria and the ACR criteria is the absence of items asses-
sing the subjective component of the disease in the
latter. Indeed, the ACR criteria do not target the general
population but only patients with suspected SS, who
complain most of the time of sicca symptoms as in our
study. Conversely, the AECG criteria may be applied to
any patient thanks to the inclusion of the symptoms in
items 1 and 2 (see Table 1). However, the preliminary
European criteria and then the AECG criteria were not
designed to be used in the general population, since the
control patients enrolled in their development study
‘were to be selected from those subjects referred to an
SS expert because of ocular or oral signs and symptoms
that simulated the clinical manifestations of SS, and for
whom a complete evaluation was justified in order to es-
tablish a differential diagnosis’ [11]. The precise diagnos-
tic value of several questionnaires assessing ocular and
oral symptoms has been carefully evaluated in these pa-
tients with suspected SS [12]. Such questionnaires may
be valid tools for SS screening in the general population
[8], but in our study the subjective symptoms did not
participate in the discrepancy between AECG and ACR
criteria, since nearly all patients had sicca complaints.
An earlier study compared the AECG criteria, the
ACR criteria and the Japanese classification criteria sets
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for SS [13]. Taking the physician’s diagnosis as the refer-
ence standard, the AECG and ACR criteria sets had
78.6% and 77.5% sensitivity, respectively, and 90.4% and
83.5% specificity.
However, a direct comparison of the AECG and ACR
criteria sets in terms of sensitivity and specificity, taking
the physician’s diagnosis as the reference standard, may
be inherently biased, as physicians probably rely heavily
on the currently used AECG criteria set to diagnose SS.
The resulting circular reasoning may overestimate the
metrological features of the AECG criteria set.
Classification criteria for systemic diseases such as SS,
rheumatoid arthritis, systemic lupus erythematosus, sys-
temic sclerosis and inflammatory myopathies are de-
signed to improve the homogeneity of populations
enrolled in clinical studies, in order to allow valid com-
parisons across studies [14-17]. Since no specific refer-
ence standard is available for diagnosing these complex
diseases, classification criteria are often used for diag-
nostic purposes, despite their limitations [18-20].
Whether classification criteria should have a higher
sensitivity or specificity is a matter of debate. Foremost,
classification criteria might be used to recruit patients in
epidemiological studies; for example, to describe the
whole spectrum of a disease including the mildest forms,
and to define prognostic factors. For such a study, the
classification criteria sensitivity should be high, even to
the detriment of their specificity, since it would not be
dangerous to include patients for whom the diagnosis is
not definitely certain. Conversely, in therapeutic trials
using potentially harmful drugs such as immunosuppres-
sant or biological therapies, one could not take the risk
of including patients who do not have the disease. In
that case, the classification criteria have to be the most
specific possible. All published classification criteria for
SS, including preliminary European and AECG criteria,
have a very high specificity (95 to 100%) but variable
sensitivity (60 to 95%) [21]. The scientific community
must achieve the widest consensus for a new classifica-
tion system, which would display the best combination
of sensitivity and specificity in order to be used univer-
sally in both epidemiological and therapeutic studies. To
achieve this goal, a large international study is war-
ranted, and the new classification criteria should include
new diagnostic tools that were validated recently, such
as salivary gland ultrasonography [4,22-24].
Conclusions
In this study, agreement was only moderate between the
AECG and ACR criteria sets. This discrepancy was mainly
ascribable to the intrinsic differences between the tests
assessing the ocular component of the criteria. Our results
suggest that the ACR criteria may detect early forms of
disease affecting specific SS subpopulations such as those
with negative anti-SSA/SSB autoantibodies. On the other
hand, the AECG criteria seem definitely more specific but
also more stringent. The existence of two different classi-
fication criteria sets for SS that select different patient
populations may cause confusion [25,26]. An international
study under the auspices of both the ACR and the
European League Against Rheumatism is warranted to
develop new universally recognized classification cri-
teria, which would probably include new procedures
such as major salivary gland ultrasonography.
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